{
    "organizations": [],
    "uuid": "189003313206207612cf0c2db948cb54b4836eba",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lexicon-announces-ema-acceptance-o/brief-lexicon-announces-ema-acceptance-of-maa-for-sotagliflozin-to-treat-adults-with-type-1-diabetes-idUSFWN1RA122",
    "ord_in_thread": 0,
    "title": "‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - Lexicon Pharmaceuticals Inc:\n* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T14:21:00.000+03:00",
    "crawled": "2018-03-30T13:26:25.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "lexicon",
        "pharmaceutical",
        "inc",
        "pharmaceutical",
        "announces",
        "ema",
        "acceptance",
        "marketing",
        "authorization",
        "application",
        "maa",
        "sotagliflozin",
        "treat",
        "adult",
        "type",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}